Augmented humoral and anaphylactic responses in FcγRII-deficient mice

T Takai, M Ono, M Hikida, H Ohmori, JV Ravetch - Nature, 1996 - nature.com
T Takai, M Ono, M Hikida, H Ohmori, JV Ravetch
Nature, 1996nature.com
DESPITE its widespread distribution on both lymphoid and myeloid cells, the biological role
of the low-affinity immuno-globulin-G receptor, FcγRII, is not fully understood. Defects in this
receptor or its signalling pathway in B cells result in perturbations in immune-complex-
mediated feedback inhibition of antibody production1–6. We now report that FcγRII-deficient
animals display elevated immunoglobulin levels in response to both thymus-dependent and
thymus-independent antigens. Additionally, the effector arm of the allergic response is …
Abstract
DESPITE its widespread distribution on both lymphoid and myeloid cells, the biological role of the low-affinity immuno-globulin-G receptor, FcγRII, is not fully understood. Defects in this receptor or its signalling pathway in B cells result in perturbations in immune-complex-mediated feedback inhibition of antibody production1–6. We now report that FcγRII-deficient animals display elevated immunoglobulin levels in response to both thymus-dependent and thymus-independent antigens. Additionally, the effector arm of the allergic response is perturbed in these mice. Mast cells from FcγRII−/− are highly sensitive to IgG-triggered degranulation, in contrast to their wild-type counterparts. FcγRII-deficient mice demonstrate an enhanced passive cutaneous analphylaxis reaction, the result of a decreased threshold for mast-cell activation by FcγRIII cross-linking. These results demonstrate that FcγRII acts as a general negative regulator of immune-complex-triggered activation in vivo for both the afferent and efferent limbs of the immune response. Exploiting this property offers new therapeutic opportunities for the treatment of allergic and autoimmune disorders.
nature.com